The industry has and continues to be under significant pressure from policy-makers to allow the publication of section eight of the PBAC meeting agenda - pricing matters - but this is one of the few areas of the system over which the industry holds virtually all the power. …
Latest Video
New Stories
-
Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances
November 26, 2025 - - Australian Biotech -
Slade Pharmacy marks anniversary with record research contributions at conferences
November 26, 2025 - - Latest News -
US secures significant price reductions on 15 medicines in second round of medicare negotiations
November 26, 2025 - - Latest News -
The US and UK edging close to an agreement on pharmaceutical pricing
November 26, 2025 - - Latest News -
US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout
November 26, 2025 - - Australian Biotech -
Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model
November 26, 2025 - - Australian Biotech -
Race Oncology secures human ethics approval for lung cancer trial of RC220
November 26, 2025 - - Australian Biotech